research:treatment_pathways_in_cancer_12mo
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision Last revision Both sides next revision | ||
|
research:treatment_pathways_in_cancer_12mo [2017/12/19 07:27] rchen |
research:treatment_pathways_in_cancer_12mo [2017/12/19 20:15] rchen |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| - | ====== Early Treatment Pathways in Patients with Cancer ====== | + | ====== Treatment Pathways in Patients with Cancer ====== |
| Line 8: | Line 8: | ||
| **Rationale:** Despite our recent characterization of treatment pathways, there is still little known about the prevalence real-world pathways for the treatment of chronic co-morbid conditions in patients with cancer. While numerous treatment guidelines exist for chronic conditions, it is unclear whether such guidelines are appropriate or followed for cancer patients and how real-world cancer patients are treated for such diseases. Understanding these pathways will establish context around questions of drug utilization, effectiveness, and adherence in this uniquely vulnerable population, and also demonstrate the feasibility of carrying out large-scale network studies in patients with cancer. | **Rationale:** Despite our recent characterization of treatment pathways, there is still little known about the prevalence real-world pathways for the treatment of chronic co-morbid conditions in patients with cancer. While numerous treatment guidelines exist for chronic conditions, it is unclear whether such guidelines are appropriate or followed for cancer patients and how real-world cancer patients are treated for such diseases. Understanding these pathways will establish context around questions of drug utilization, effectiveness, and adherence in this uniquely vulnerable population, and also demonstrate the feasibility of carrying out large-scale network studies in patients with cancer. | ||
| - | **Project Leads:** George Hripcsak | + | **Project Leads:** George Hripcsak, Ray Chen, Thomas Falconer |
| **Coordinating Institution(s):** Columbia University | **Coordinating Institution(s):** Columbia University | ||
| - | ** Additional Participants:** TBD | + | ** Additional Participants:** Janssen R&D |
| - | **Full Protocol:** [[https://github.com/OHDSI/StudyProtocols/blob/master/Study%202%20-%20Treatment%20Pathways%2012mo/OHDSITreatmentPathwaysinChronicDisease12monthprotocol.docx?raw=true|Chronic Disease Treatment Pathways 12-month Protocol]] | + | **Full Protocol:** [[https://github.com/rchen-cumc/StudyProtocols/blob/master/TreatmentPathways-Cancer12mo/Protocol/OHDSITxPathCancer12moProtocol.docx|Treatment Pathways in Patients with Cancer 12 months Study Protocol]] |
| **Initial Proposal Date:** 12/19/2017 | **Initial Proposal Date:** 12/19/2017 | ||
| Line 34: | Line 34: | ||
| ===== Code ===== | ===== Code ===== | ||
| - | [[To be released soon]] | + | [[https://github.com/rchen-cumc/StudyProtocols/tree/master/TreatmentPathways-Cancer12mo|Github repo]] |
| ===== Discussion ===== | ===== Discussion ===== | ||
| - | [[TBD]] | + | [[http://forums.ohdsi.org/t/ohdsi-study-treatment-pathways-in-patients-with-cancer/3778|Cancer Treatment Pathways Discussion Thread]] |
| ===== Datasets Run ===== | ===== Datasets Run ===== | ||
research/treatment_pathways_in_cancer_12mo.txt ยท Last modified: 2017/12/19 20:15 by rchen
Page Tools
